HilleVax, Inc. (NASDAQ:HLVX) Receives Consensus Rating of “Hold” from Analysts

Shares of HilleVax, Inc. (NASDAQ:HLVX) have received a consensus rating of “Hold” from the six analysts that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.20.

HLVX has been the subject of several recent research reports. Leerink Partnrs cut HilleVax from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 9th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $5.00 price target (down previously from $24.00) on shares of HilleVax in a report on Monday, July 8th. Guggenheim cut HilleVax from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. HC Wainwright reissued a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a report on Monday, August 12th. Finally, Leerink Partners cut HilleVax from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $28.00 to $2.00 in a report on Tuesday, July 9th.

Institutional Investors Weigh In On HilleVax

A number of hedge funds and other institutional investors have recently bought and sold shares of HLVX. EntryPoint Capital LLC acquired a new stake in HilleVax during the 1st quarter valued at $80,000. Tidal Investments LLC acquired a new stake in HilleVax during the 1st quarter valued at $207,000. Maven Securities LTD acquired a new stake in HilleVax during the 2nd quarter valued at $217,000. Algert Global LLC acquired a new stake in HilleVax during the 2nd quarter valued at $519,000. Finally, Swiss National Bank increased its holdings in HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after purchasing an additional 7,000 shares in the last quarter. 86.42% of the stock is owned by institutional investors and hedge funds.

HilleVax Stock Down 0.6 %

HilleVax stock opened at $1.80 on Monday. The business has a 50 day moving average price of $1.80 and a two-hundred day moving average price of $9.59. The stock has a market cap of $89.50 million, a price-to-earnings ratio of -0.55 and a beta of 0.81. HilleVax has a 12 month low of $1.55 and a 12 month high of $20.22.

HilleVax (NASDAQ:HLVX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.10). On average, analysts expect that HilleVax will post -2.47 earnings per share for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.